Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17662433 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL16248631 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL11956480 | 0.95 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL16248528 | 0.95 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL16248523 | 0.95 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL24239548 | 0.89 | OPRK1 (0.33) | KDM4EALDH1A1ITGB3ITGA2B | |
| SCHEMBL19062769 | 0.89 | OPRK1 (0.33) | KDM4EALDH1A1ITGB3ITGA2B | |
| SCHEMBL22800098 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL22799569 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL11956481 | 0.87 | CYP2D6 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023057813-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-8709998-B2 | Peptide vectors | IPSEN PHARMA S.A.S. (FR) | 2014-04-29 | — | — | US | disclosed |
| US-8709998-B2 | Peptide vectors | IPSEN PHARMA S.A.S. (FR) | 2014-04-29 | — | — | US | disclosed |
| US-8236762-B2 | Peptide-cytotoxic conjugates | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| US-20100113367-A1 | PEPTIDE-CYTOTOXIC CONJUGATES | IPSEN PHARMA S.A.S. (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20070093645-A1 | Peptide vectors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION (FR) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | KDM4E 685/4885ALDH1A1 1047/4885ITGB3 528/4885 |
| US-20100113367-A1 | PEPTIDE-CYTOTOXIC CONJUGATES | TP53, VIP, MCL1 | KDM4E 4485/4885ALDH1A1 3716/4885ITGB3 1125/4885 |
| US-20070093645-A1 | Peptide vectors | TP53, VIP, XIAP | KDM4E 4575/4885ALDH1A1 4534/4885ITGB3 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.